First line dual therapy for gonorrhoea to limit the spread of antimicrobial resistance.
HIV and STI Department, National Infection Service, Public Health England, London NW9 5EQ, UK.
Hamish
H
Mohammed
HIV and STI Department, National Infection Service, Public Health England, London NW9 5EQ, UK.
Bersabeh
B
Sile
HIV and STI Department, National Infection Service, Public Health England, London NW9 5EQ, UK.
Martina
M
Furegato
HIV and STI Department, National Infection Service, Public Health England, London NW9 5EQ, UK.
Sarah
S
Woodhall
HIV and STI Department, National Infection Service, Public Health England, London NW9 5EQ, UK.
Helen
H
Fifer
HIV and STI Department, National Infection Service, Public Health England, London NW9 5EQ, UK.
Gwenda
G
Hughes
D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D017963:Azithromycin / Q000008:administration & dosage*; D002443:Ceftriaxone / Q000008:administration & dosage*; D024881:Drug Resistance, Bacterial / Q000187:drug effects; D004359:Drug Therapy, Combination / Q000379:methods; D006069:Gonorrhea / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D009344:Neisseria gonorrhoeae / Q000187:drug effects; D017410:Practice Guidelines as Topic
D000900:Anti-Bacterial Agents; D002443:Ceftriaxone; D017963:Azithromycin